Please ensure Javascript is enabled for purposes of website accessibility
Search
▲ S&P 500 +---% | ▲ Stock Advisor +---%
Accessibility Log In Help
Accessibility Menu
Arrow-Thin-Down
S&P 500
6,363.35
+0.1%
+$4.44
Arrow-Thin-Down
DJI
44,693.91
-0.7%
-$316.38
Arrow-Thin-Down
NASDAQ
21,057.96
+0.2%
+$37.94
Arrow-Thin-Down
Bitcoin
118,429.00
-0.2%
-286.85
Arrow-Thin-Down
AAPL
$213.98
-0.1%
-$0.17
Arrow-Thin-Down
AMZN
$232.40
+1.8%
+$4.11
Arrow-Thin-Down
GOOG
$193.33
+1.0%
+$1.82
Arrow-Thin-Down
META
$715.59
+0.3%
+$2.01
Arrow-Thin-Down
MSFT
$511.37
+1.1%
+$5.50
Arrow-Thin-Down
NVDA
$173.76
+1.7%
+$2.98
Arrow-Thin-Down
TSLA
$305.67
-8.1%
-$26.89
Daily Stock Gainers Daily Stock Losers Most Active Stocks
Home > Markets > Top Stock Losers

Biggest Stock Losers Today

View:

Top Stock Losers

Explore the biggest stock losers today along with up-to-date performance data, including the latest price, share price changes, trading volume, and more. We cover the top stock losers and decliners every day with market data, news, and analysis from our Foolish experts.

Related Articles

Featured Article
NovoCure Q2 Revenue Jumps 6 Percent
JesterAI | Jul 24, 2025
Foolcom-Featured.png
Novocure: Steady Ahead of Key Milestones
Lou Whiteman | Jul 24, 2025
GettyImages-1477483008
NVE (NVEC) Q1 2026 Earnings Call Transcript
Motley Fool Transcribing | Jul 23, 2025
featured-transcript-logo-template.jpg
Why NovoCure Stock Skyrocketed This Week
Johnny Rice | Apr 25, 2025
NovoCure Cancer
Why NovoCure Stock Leaped 4% Higher Today
Eric Volkman | Apr 24, 2025
Person in a lab gazing into a microscope
NovoCure Surpasses Q1 Expectations
JesterAI | Apr 24, 2025
NovoCure posted stronger-than-expected Q1 2025 results, driven by revenue and GAAP earnings surpassing estimates.
Foolcom-Featured.png
Why NovoCure Stock Was Withering on Wednesday
Eric Volkman | Apr 16, 2025
Person in a lab gazing into a microscope
Prediction: Novocure (NVCR) Will Beat the Market. Here's Why
Motley Fool YouTube | Jul 3, 2025
NVCR_03.04.25
NovoCure (NVCR) Q4 2024 Earnings Call Transcript
Motley Fool Transcribing | Feb 27, 2025
NVCR earnings call for the period ending December 31, 2024.
featured-transcript-logo
NovoCure Q4 EPS Misses, Revenue Matches
JesterAI | Feb 27, 2025
NovoCure reported a solid jump in revenue, but earnings fell short due to rising costs and adoption challenges.
scientists examine cell make up microscope biotech.jpg

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services